a friend of mine TMB-low and MSS, KRAS-WT, (after FOLFOX+Cetuximab, FOLFIRI+Avastin, LONSURF, Panitumumab, Mitomycin (no option for STIRVAGA) is heading now into an experimental therapy at the Hallwang Clinic with a MEK Inhibitor in combination with Pembrolizumab and Ipilimumab. I was quite excited to hear about this combo but I wasn't able to provide a feedback except the early trial data that have shown some, maybe even promising results - http://ascopubs.org/doi/abs/10.1200/JCO ... suppl.3502 , https://www.primeoncology.org/primeline ... r-mss-crc/ , looking at the most recent trial data https://www.targetedonc.com/news/atezol ... ib-in-mcrc , I found the idea interesting to rather use a PD-1 in combination with a MEK inhibitor instead of PD-L1 and even thinking of a combination with Ipilimumab. Particularly, who really tolerates Regorafenib (?). My friend has met a patient at the Hallwang Clinic who (so far) is doing well under this therapy combination, now beeing 6 months on it, with a response to the therapy after 3 months. No drainages currently needed. Personally, I think it is the right way to think for MSS in a challenging situation and limited therapy options.
But is there anyone here who can share some personal clinical experience with MEK plus Atezo or any other PD-1 antibodies, or even the combination with Ipilimumab, or has been at the Hallwang Clinic as well for this therapy combination? Thank you